One-month delay in methotrexate initiation on rheumatoid arthritis outcomes: One-year ancillary analysis of the VACIMRA trial
Clicks: 5
ID: 314700
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Popular Article
1.2
/100
5 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
PopularRanked #13 of 200 articles by views in Lara D. Veeken
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 200 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Objectives The VACIMRA trial demonstrated that delaying methotrexate initiation in rheumatoid arthritis (RA) by one month after the 13-valent pneumococcal conjugate vaccine (PCV13) improves humoral responses at 1 and 12 months. Whether this delay impacts disease activity and radiographic progression over one year remains uncertain. Methods This ancillary study compared changes in disease activity (DAS28-ESR) from inclusion (M0) to months 1, 2, 3, 6, and 12 between patients with early RA who started methotrexate immediately vs one month after PCV13. Structural progression was assessed using the van der Heijde-modified Sharp score (mSHS) on X-rays at inclusion, 6 and 12 months. The primary outcome was the proportion of patients in remission (DAS28-ESR < 2.6) or low disease activity (LDA) (DAS28-ESR ≤ 3.2) at one year. Results Among 276 VACIMRA participants, 100 were enrolled at the Montpellier center (96 analyzable at M0, 83 at M12). Both groups had similar baseline characteristics: mean age 58 ± 14 years, DAS28-ESR 4.88 ± 0.94, total mSHS 1.53 ± 3.62. Treatments during follow-up were comparable except for methotrexate cumulative dose at 1, 3, 6 months. At 12 months, remission (53.7% vs 46.3%, p= 0.51) and LDA rate (75.6% vs 61.0%, p= 0.15) were similar. DAS28-ESR was similar at 1 and 3 months but favored the DELAY group at 6 (2.66 ± 1.07 vs 3.28 ± 1.34, p= 0.02) and 12 months (2.23 ± 1.03 vs 3.00 ± 1.16, p< 0.01). mSHS progression was comparable at 6 and 12 months. Conclusion Deferring methotrexate for one month after PCV13 to enhance immunity did not worsen RA disease control, radiographic progression, or treatment escalation after one year of follow-up.
| Reference Key |
openalex_W7162113684
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Theresa Than, Gael Mouterde, Claire Immediato Daien, Cedric Lukas, Anouck Rémy-Moulard, Cécile Gaujoux Viala, Joana Pissarra, Héléna Huguet, Marie-Christine Picot, Jacques Morel |
| Journal | Lara D. Veeken |
| Year | 2026 |
| DOI |
10.1093/rheumatology/keag270
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.